Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing Morbidity in First-Episode Schizophrenia
NCT00000374Phase 4Completed
- Sponsor
- Northwell Health
- Start
- Sep 1998
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in schizophrenia, schizophreniform disorder and schizoaffective disorder comparing Olanzapine with Risperidone (2 arms). Primary endpoint: Treatment response at 8 weeks. Started Sep 1998; status: completed.
02
Drugs
olanzapinerisperidone
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorder
Beyond the preview
Go deeper on NCT00000374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000374.